You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRitonavir
Accession NumberDB00503  (APRD00312)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]
Structure
Thumb
Synonyms
Norvir
Ritonavir
Ritonavirum
External Identifiers
  • Abbott 84538
  • ABT 538
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Norvirsolution80 mg/mLoralAbb Vie Inc.2010-05-06Not applicableUs
Norvirsolution80 mgoralAbbvie Corporation1996-09-25Not applicableCanada
Norvirtablet, film coated100 mg/1oralAbb Vie Inc.2010-05-06Not applicableUs
Norvirtablet100 mgoralAbbvie Corporation2010-12-17Not applicableCanada
Norvircapsule100 mg/1oralAbb Vie Inc.2010-05-06Not applicableUs
Norvircapsule100 mgoralAbbvie Corporation1996-09-162012-11-08Canada
Norvirtablet, film coated100 mg/1oralREMEDYREPACK INC.2015-07-30Not applicableUs
Norvir Seccapsule100 mgoralAbbvie Corporation2000-01-072014-11-25Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BusvirConifarma
EmpetusEmcure
NormuneGrey Inversiones
Brand mixtures
NameLabellerIngredients
Holkira PakAbbvie Corporation
KaletraAbb Vie Inc.
TechnivieAbb Vie Inc.
Viekira PakAbb Vie Inc.
SaltsNot Available
Categories
UNIIO3J8G9O825
CAS number155213-67-5
WeightAverage: 720.944
Monoisotopic: 720.312760056
Chemical FormulaC37H48N6O5S2
InChI KeyInChIKey=NCDNCNXCDXHOMX-XGKFQTDJSA-N
InChI
InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1
IUPAC Name
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate
SMILES
CC(C)[[email protected]](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[[email protected]](C[[email protected]](O)[[email protected]](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-carbamoyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an carbamoyl group at its terminal nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-carbamoyl-alpha amino acids and derivatives
Alternative Parents
Substituents
  • N-carbamoyl-alpha-amino acid or derivatives
  • Alpha-amino acid amide
  • Amphetamine or derivatives
  • 2,4-disubstituted 1,3-thiazole
  • Fatty acyl
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Thiazole
  • Azole
  • Urea
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationIndicated in combination with other antiretroviral agents for the treatment of HIV-infection.
PharmacodynamicsRitonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Ritonavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Mechanism of actionRitonavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Related Articles
AbsorptionThe absolute bioavailability of ritonavir has not been determined.
Volume of distributionNot Available
Protein binding98-99%
Metabolism

Hepatic. Five metabolites have been identified. The isopropylthiazole oxidation metabolite (M-2) is the major metabolite and has antiviral activity similar to that of ritonavir, however, plasma concentrations are low. The cytochrome P450 enzymes CYP3A and CYP2D6 are primarily involved in the metabolism of ritonavir.

SubstrateEnzymesProduct
Ritonavir
N-DesmethylritonavirDetails
Ritonavir
Hydroxy RitonavirDetails
Ritonavir
Ritonavir metabolite M1Details
Ritonavir
Ritonavir metabolite M11Details
Route of eliminationNot Available
Half life3-5 hours
ClearanceNot Available
ToxicityHuman experience of acute overdose with ritonavir is limited. One patient in clinical trials took ritonavir 1500 mg/day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose. The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice.
Affected organisms
  • Human Immunodeficiency Virus
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7195
Blood Brain Barrier-0.9717
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8307
P-glycoprotein inhibitor IInhibitor0.8317
P-glycoprotein inhibitor IINon-inhibitor0.8753
Renal organic cation transporterNon-inhibitor0.9009
CYP450 2C9 substrateNon-substrate0.694
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5973
CYP450 1A2 substrateNon-inhibitor0.67
CYP450 2C9 inhibitorNon-inhibitor0.6229
CYP450 2D6 inhibitorNon-inhibitor0.8424
CYP450 2C19 inhibitorInhibitor0.5399
CYP450 3A4 inhibitorInhibitor0.5843
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5946
Ames testNon AMES toxic0.7378
CarcinogenicityNon-carcinogens0.8664
BiodegradationNot ready biodegradable0.9633
Rat acute toxicity2.6154 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9774
hERG inhibition (predictor II)Inhibitor0.8457
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott laboratories pharmaceutical products div
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
Kit; tabletoral
Capsuleoral
Solutionoral
Tabletoral
Tablet, film coatedoral
Capsuleoral100 mg
Capsuleoral100 mg/1
Solutionoral80 mg
Solutionoral80 mg/mL
Tabletoral100 mg
Tablet, film coatedoral100 mg/1
Kit
Prices
Unit descriptionCostUnit
Norvir 100 mg softgel cap10.29USD softgel capsule
Norvir 100 mg tablet10.29USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2135890 No1996-08-272013-12-16Canada
CA2178632 No2006-04-112015-01-03Canada
US5541206 No1993-07-302013-07-30Us
US5914332 Yes1996-06-132016-06-13Us
US6037157 Yes1996-12-262016-12-26Us
US6232333 Yes1998-05-072018-05-07Us
US6284767 Yes1996-08-152016-08-15Us
US6458818 Yes1998-05-072018-05-07Us
US6521651 Yes1998-05-072018-05-07Us
US6703403 Yes1996-12-262016-12-26Us
US6911214 Yes2002-05-282022-05-28Us
US7141593 Yes2000-11-222020-11-22Us
US7148359 Yes2000-01-192020-01-19Us
US7364752 Yes2001-05-102021-05-10Us
US7432294 Yes2000-11-222020-11-22Us
US8025899 Yes2008-06-142028-06-14Us
US8188104 No2009-05-172029-05-17Us
US8268349 Yes2005-02-252025-02-25Us
US8309613 Yes2005-06-242025-06-24Us
US8377952 Yes2008-04-222028-04-22Us
US8399015 Yes2005-02-252025-02-25Us
US8420596 Yes2011-10-102031-10-10Us
US8466159 No2012-09-042032-09-04Us
US8470347 Yes2007-03-172027-03-17Us
US8492386 No2012-09-042032-09-04Us
US8501219 No2001-11-282021-11-28Us
US8501238 No2008-09-172028-09-17Us
US8642538 No2009-09-102029-09-10Us
US8680106 No2012-09-042032-09-04Us
US8685984 No2012-09-042032-09-04Us
US8686026 No2011-06-092031-06-09Us
US8691878 Yes2005-02-252025-02-25Us
US8691938 No2012-04-132032-04-13Us
US9006387 No2010-06-102030-06-10Us
US9044480 No2011-04-102031-04-10Us
US9139536 No2008-11-092028-11-09Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityPractically insolubleNot Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00126 mg/mLALOGPS
logP4.24ALOGPS
logP5.22ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)13.68ChemAxon
pKa (Strongest Basic)2.84ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area145.78 Å2ChemAxon
Rotatable Bond Count18ChemAxon
Refractivity194.59 m3·mol-1ChemAxon
Polarizability77.4 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US5484801
General ReferencesNot Available
External Links
ATC CodesJ05AX67J05AR10J05AE03J05AX66
AHFS Codes
  • 08:18.08.08
PDB Entries
FDA labelDownload (350 KB)
MSDSDownload (57.4 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Ritonavir.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Ritonavir.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Ritonavir.
AbirateroneThe serum concentration of Ritonavir can be increased when it is combined with Abiraterone.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Ritonavir.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Ritonavir.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Ritonavir.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Ritonavir.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Ritonavir.
AcetaminophenThe serum concentration of Ritonavir can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ritonavir.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Ritonavir.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Ritonavir.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Ritonavir.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Ritonavir.
AfatinibThe serum concentration of Ritonavir can be increased when it is combined with Afatinib.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Ritonavir.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Ritonavir.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Ritonavir.
AlbendazoleThe serum concentration of Ritonavir can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Ritonavir.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Ritonavir.
AlectinibThe serum concentration of Ritonavir can be increased when it is combined with Alectinib.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Ritonavir.
AlfentanilThe serum concentration of Ritonavir can be increased when it is combined with Alfentanil.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Ritonavir.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Ritonavir.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Ritonavir.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Ritonavir.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Ritonavir.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ritonavir.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Ritonavir.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Ritonavir.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Ritonavir.
AmantadineThe serum concentration of Ritonavir can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Ritonavir.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Ritonavir.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Ritonavir.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Ritonavir.
Aminohippuric acidThe serum concentration of Ritonavir can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Ritonavir.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Ritonavir.
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Ritonavir.
AmiodaroneThe serum concentration of Ritonavir can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ritonavir.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Ritonavir.
AmlodipineThe serum concentration of Ritonavir can be increased when it is combined with Amlodipine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Ritonavir.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Ritonavir.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Ritonavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Ritonavir.
AmprenavirThe serum concentration of Ritonavir can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Ritonavir can be increased when it is combined with Amsacrine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Ritonavir.
AnagrelideRitonavir may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Ritonavir.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ritonavir.
ApremilastThe metabolism of Apremilast can be decreased when combined with Ritonavir.
AprepitantThe serum concentration of Ritonavir can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Ritonavir.
AprindineThe metabolism of Aprindine can be decreased when combined with Ritonavir.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Ritonavir.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Ritonavir.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Ritonavir.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ritonavir.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Ritonavir.
ArtemetherThe metabolism of Artemether can be decreased when combined with Ritonavir.
AsenapineThe metabolism of Asenapine can be decreased when combined with Ritonavir.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Ritonavir.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Ritonavir.
AtazanavirThe serum concentration of Ritonavir can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Ritonavir.
AtenololThe serum concentration of Ritonavir can be increased when it is combined with Atenolol.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Ritonavir.
AtomoxetineThe metabolism of Ritonavir can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ritonavir.
AtovaquoneThe serum concentration of Atovaquone can be decreased when it is combined with Ritonavir.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Ritonavir.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ritonavir.
AzelastineThe metabolism of Azelastine can be decreased when combined with Ritonavir.
AzelastineThe serum concentration of Ritonavir can be increased when it is combined with Azelastine.
AzithromycinRitonavir may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Ritonavir can be increased when it is combined with Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Ritonavir.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Ritonavir.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ritonavir.
BedaquilineRitonavir may increase the QTc-prolonging activities of Bedaquiline.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Ritonavir.
BenzocaineThe serum concentration of Ritonavir can be increased when it is combined with Benzocaine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Ritonavir.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Ritonavir.
BepridilThe serum concentration of Ritonavir can be increased when it is combined with Bepridil.
BepridilThe metabolism of Bepridil can be decreased when combined with Ritonavir.
BeraprostThe metabolism of Beraprost can be decreased when combined with Ritonavir.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Ritonavir.
BetaxololThe metabolism of Ritonavir can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Ritonavir can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Ritonavir.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Ritonavir.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Ritonavir.
BiperidenThe serum concentration of Ritonavir can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Ritonavir.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Ritonavir.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Ritonavir.
BortezomibThe metabolism of Ritonavir can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ritonavir can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Ritonavir.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ritonavir.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ritonavir.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Ritonavir.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Ritonavir.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Ritonavir.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Ritonavir.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Ritonavir.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Ritonavir.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Ritonavir.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Ritonavir.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Ritonavir.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Ritonavir.
BuprenorphineThe serum concentration of Ritonavir can be increased when it is combined with Buprenorphine.
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Ritonavir.
BupropionThe metabolism of Ritonavir can be decreased when combined with Bupropion.
BuspironeThe metabolism of Buspirone can be decreased when combined with Ritonavir.
BuspironeThe serum concentration of Ritonavir can be increased when it is combined with Buspirone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Ritonavir.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Ritonavir.
CabazitaxelThe serum concentration of Ritonavir can be increased when it is combined with Cabazitaxel.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Ritonavir.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Ritonavir.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Ritonavir.
CaffeineThe serum concentration of Ritonavir can be increased when it is combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Ritonavir.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Ritonavir.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ritonavir.
CanagliflozinThe serum concentration of Ritonavir can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Ritonavir can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Ritonavir can be increased when it is combined with Captopril.
CaptoprilThe metabolism of Captopril can be decreased when combined with Ritonavir.
CarbamazepineThe serum concentration of Ritonavir can be decreased when it is combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Ritonavir.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Ritonavir.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Ritonavir.
CarteololThe metabolism of Carteolol can be decreased when combined with Ritonavir.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Ritonavir.
CarvedilolThe serum concentration of Ritonavir can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Ritonavir can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ritonavir.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Ritonavir.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Ritonavir.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Ritonavir.
CeritinibThe serum concentration of Ritonavir can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Ritonavir.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Ritonavir.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Ritonavir.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Ritonavir.
ChloroquineRitonavir may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Ritonavir can be increased when it is combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Ritonavir.
ChlorpromazineRitonavir may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe serum concentration of Ritonavir can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ritonavir.
ChlorpropamideThe serum concentration of Ritonavir can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Ritonavir can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Ritonavir.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Ritonavir.
CholesterolThe serum concentration of Ritonavir can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Ritonavir can be decreased when it is combined with Cholic Acid.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Ritonavir.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ritonavir.
CilazaprilThe serum concentration of Ritonavir can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Ritonavir.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Ritonavir.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Ritonavir.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Ritonavir.
CiprofloxacinRitonavir may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Ritonavir can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Ritonavir.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Ritonavir.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Ritonavir.
CitalopramThe serum concentration of Ritonavir can be increased when it is combined with Citalopram.
ClarithromycinRitonavir may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe serum concentration of Ritonavir can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Ritonavir can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Ritonavir.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Ritonavir.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Ritonavir.
ClobazamThe metabolism of Ritonavir can be decreased when combined with Clobazam.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Ritonavir.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Ritonavir.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Ritonavir.
ClofazimineThe serum concentration of Ritonavir can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Ritonavir.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Ritonavir.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Ritonavir.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Ritonavir.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Ritonavir.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Ritonavir.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Ritonavir.
ClopidogrelThe metabolism of Ritonavir can be decreased when combined with Clopidogrel.
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Ritonavir.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Ritonavir.
ClotrimazoleThe metabolism of Ritonavir can be decreased when combined with Clotrimazole.
ClozapineRitonavir may increase the QTc-prolonging activities of Clozapine.
ClozapineThe metabolism of Ritonavir can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Ritonavir can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ritonavir.
CocaineThe metabolism of Cocaine can be decreased when combined with Ritonavir.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Ritonavir.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Ritonavir.
ColchicineThe serum concentration of Ritonavir can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Ritonavir can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Ritonavir can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Ritonavir.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Ritonavir.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Ritonavir.
CrizotinibThe metabolism of Ritonavir can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ritonavir.
CyclophosphamideThe risk or severity of adverse effects can be increased when Ritonavir is combined with Cyclophosphamide.
CyclophosphamideThe serum concentration of Ritonavir can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Ritonavir can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Ritonavir.
Cyproterone acetateThe serum concentration of Ritonavir can be decreased when it is combined with Cyproterone acetate.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Ritonavir.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Ritonavir.
DabrafenibThe serum concentration of Ritonavir can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Ritonavir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Ritonavir.
DactinomycinThe serum concentration of Ritonavir can be increased when it is combined with Dactinomycin.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Ritonavir.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Ritonavir.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Ritonavir.
DapsoneThe metabolism of Dapsone can be decreased when combined with Ritonavir.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Ritonavir.
DarunavirThe serum concentration of Ritonavir can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Ritonavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Ritonavir.
DasatinibThe serum concentration of Ritonavir can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Ritonavir.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Ritonavir.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Ritonavir.
DeferasiroxThe serum concentration of Ritonavir can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Ritonavir.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Ritonavir.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Ritonavir.
DelavirdineThe metabolism of Ritonavir can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Ritonavir.
DesloratadineThe serum concentration of Ritonavir can be increased when it is combined with Desloratadine.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Ritonavir.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Ritonavir.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Ritonavir.
DexamethasoneThe serum concentration of Ritonavir can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Ritonavir.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Ritonavir.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Ritonavir.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Ritonavir.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Ritonavir.
DextromethorphanThe serum concentration of Ritonavir can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Ritonavir.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ritonavir.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Ritonavir.
DiclofenacThe serum concentration of Ritonavir can be increased when it is combined with Diclofenac.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Ritonavir.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ritonavir.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Ritonavir.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Ritonavir.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Ritonavir.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Ritonavir.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ritonavir.
DigoxinThe serum concentration of Ritonavir can be decreased when it is combined with Digoxin.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Ritonavir.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Ritonavir.
DihydroergotamineThe metabolism of Ritonavir can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Ritonavir.
DiltiazemThe metabolism of Ritonavir can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Ritonavir.
DiphenhydramineThe metabolism of Ritonavir can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Ritonavir.
DipyridamoleThe serum concentration of Ritonavir can be increased when it is combined with Dipyridamole.
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Ritonavir.
DisulfiramThe risk or severity of adverse effects can be increased when Ritonavir is combined with Disulfiram.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Ritonavir.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Ritonavir.
DolasetronRitonavir may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ritonavir.
DonepezilThe metabolism of Donepezil can be decreased when combined with Ritonavir.
DopamineThe metabolism of Dopamine can be decreased when combined with Ritonavir.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Ritonavir.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Ritonavir.
DoxazosinThe serum concentration of Ritonavir can be increased when it is combined with Doxazosin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Ritonavir.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Ritonavir.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Ritonavir.
DoxycyclineThe metabolism of Ritonavir can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Ritonavir.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Ritonavir.
DronedaroneThe metabolism of Ritonavir can be decreased when combined with Dronedarone.
DroperidolRitonavir may increase the QTc-prolonging activities of Droperidol.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Ritonavir.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ritonavir.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Ritonavir.
DuloxetineThe metabolism of Ritonavir can be decreased when combined with Duloxetine.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Ritonavir.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Ritonavir.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Ritonavir.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ritonavir.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Ritonavir.
ElbasvirThe serum concentration of Ritonavir can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ritonavir.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Ritonavir.
EliglustatThe metabolism of Ritonavir can be decreased when combined with Eliglustat.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Ritonavir.
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Ritonavir.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Ritonavir.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ritonavir.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Ritonavir.
EnalaprilThe serum concentration of Ritonavir can be increased when it is combined with Enalapril.
EncainideThe metabolism of Encainide can be decreased when combined with Ritonavir.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Ritonavir.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Ritonavir.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Ritonavir.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Ritonavir.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Ritonavir.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Ritonavir.
EquilinThe serum concentration of Equilin can be increased when it is combined with Ritonavir.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Ritonavir.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ritonavir.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Ritonavir.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Ritonavir.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Ritonavir.
ErythromycinRitonavir may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Ritonavir can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Ritonavir.
Eslicarbazepine acetateThe serum concentration of Ritonavir can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Ritonavir.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Ritonavir.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Ritonavir.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Ritonavir.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Ritonavir.
EstramustineThe metabolism of Estramustine can be decreased when combined with Ritonavir.
EstramustineThe serum concentration of Ritonavir can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Ritonavir.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Ritonavir.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Ritonavir.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Ritonavir.
EthanolThe metabolism of Ethanol can be decreased when combined with Ritonavir.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Ritonavir.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Ritonavir.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Ritonavir.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Ritonavir.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Ritonavir.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Ritonavir.
EtoposideThe serum concentration of Ritonavir can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Ritonavir.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Ritonavir.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ritonavir.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Ritonavir.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Ritonavir.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Ritonavir.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Ritonavir.
FelbamateThe metabolism of Felbamate can be decreased when combined with Ritonavir.
FelodipineThe metabolism of Felodipine can be decreased when combined with Ritonavir.
FelodipineThe serum concentration of Ritonavir can be increased when it is combined with Felodipine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Ritonavir.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Ritonavir.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ritonavir.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Ritonavir.
FexofenadineThe serum concentration of Ritonavir can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Ritonavir.
FidaxomicinThe serum concentration of Ritonavir can be increased when it is combined with Fidaxomicin.
FinasterideThe metabolism of Finasteride can be decreased when combined with Ritonavir.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Ritonavir.
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Ritonavir.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ritonavir.
FluconazoleThe metabolism of Ritonavir can be decreased when combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Ritonavir.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Ritonavir.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Ritonavir.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Ritonavir.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Ritonavir.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ritonavir.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Ritonavir.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Ritonavir.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Ritonavir.
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Ritonavir.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Ritonavir.
FluoxetineThe serum concentration of Ritonavir can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Ritonavir can be increased when it is combined with Flupentixol.
FlupentixolRitonavir may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Ritonavir can be increased when it is combined with Fluphenazine.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Ritonavir.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Ritonavir.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Ritonavir.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Ritonavir.
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Ritonavir.
FlutamideThe metabolism of Flutamide can be decreased when combined with Ritonavir.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Ritonavir.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Ritonavir.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Ritonavir.
FluvoxamineThe metabolism of Ritonavir can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Ritonavir.
FosamprenavirThe metabolism of Ritonavir can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ritonavir can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Ritonavir can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Ritonavir.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Ritonavir.
Fusidic AcidThe serum concentration of Ritonavir can be increased when it is combined with Fusidic Acid.
Gadobenic acidRitonavir may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Ritonavir.
GarlicThe serum concentration of Ritonavir can be decreased when it is combined with Garlic.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Ritonavir.
GefitinibThe serum concentration of Ritonavir can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Ritonavir.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Ritonavir.
GemifloxacinRitonavir may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Ritonavir can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ritonavir.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Ritonavir.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ritonavir.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Ritonavir.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ritonavir.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Ritonavir.
GlyburideThe serum concentration of Ritonavir can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Ritonavir can be increased when it is combined with Glycerol.
GoserelinRitonavir may increase the QTc-prolonging activities of Goserelin.
Gramicidin DThe serum concentration of Ritonavir can be increased when it is combined with Gramicidin D.
GranisetronRitonavir may increase the QTc-prolonging activities of Granisetron.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Ritonavir.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Ritonavir.
GrepafloxacinThe serum concentration of Ritonavir can be increased when it is combined with Grepafloxacin.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Ritonavir.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Ritonavir.
HaloperidolRitonavir may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe serum concentration of Ritonavir can be increased when it is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Ritonavir.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Ritonavir.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Ritonavir.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Ritonavir.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Ritonavir.
HydrocortisoneThe serum concentration of Ritonavir can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Ritonavir.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Ritonavir.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Ritonavir.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Ritonavir.
IbutilideRitonavir may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Ritonavir.
IdelalisibThe serum concentration of Ritonavir can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Ritonavir resulting in a loss in efficacy.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Ritonavir.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Ritonavir.
ImatinibThe metabolism of Ritonavir can be decreased when combined with Imatinib.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Ritonavir.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ritonavir.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Ritonavir.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Ritonavir.
IndapamideThe metabolism of Indapamide can be decreased when combined with Ritonavir.
IndinavirThe serum concentration of Ritonavir can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Ritonavir.
IndomethacinThe serum concentration of Ritonavir can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ritonavir.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ritonavir.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ritonavir.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ritonavir.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ritonavir.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ritonavir.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Ritonavir.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Ritonavir.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Ritonavir.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Ritonavir.
IsavuconazoniumThe metabolism of Ritonavir can be decreased when combined with Isavuconazonium.
IsoniazidThe metabolism of Ritonavir can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ritonavir.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ritonavir.
IsradipineThe metabolism of Ritonavir can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Ritonavir.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Ritonavir.
IvacaftorThe serum concentration of Ritonavir can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Ritonavir.
IvermectinThe serum concentration of Ritonavir can be increased when it is combined with Ivermectin.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Ritonavir.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Ritonavir.
KetamineThe metabolism of Ketamine can be decreased when combined with Ritonavir.
KetamineThe serum concentration of Ritonavir can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Ritonavir.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Ritonavir.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Ritonavir.
KetoconazoleThe serum concentration of Ritonavir can be increased when it is combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Ritonavir.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Ritonavir.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Ritonavir.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Ritonavir.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Ritonavir.
LansoprazoleThe serum concentration of Ritonavir can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Ritonavir.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Ritonavir.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ritonavir.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Ritonavir.
LenvatinibRitonavir may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Ritonavir.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Ritonavir.
LeuprolideRitonavir may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Ritonavir.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Ritonavir.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Ritonavir.
LevodopaThe metabolism of Levodopa can be decreased when combined with Ritonavir.
LevofloxacinRitonavir may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Ritonavir can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Ritonavir.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Ritonavir.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Ritonavir.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Ritonavir.
LevothyroxineThe serum concentration of Ritonavir can be decreased when it is combined with Levothyroxine.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Ritonavir.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Ritonavir.
LidocaineThe serum concentration of Ritonavir can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Ritonavir.
LiothyronineThe serum concentration of Ritonavir can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Ritonavir can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Ritonavir.
LisinoprilThe serum concentration of Ritonavir can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Ritonavir.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Ritonavir.
LomustineThe metabolism of Lomustine can be decreased when combined with Ritonavir.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Ritonavir.
LoperamideThe serum concentration of Ritonavir can be increased when it is combined with Loperamide.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Ritonavir.
LopinavirThe serum concentration of Ritonavir can be increased when it is combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Ritonavir.
LoratadineThe serum concentration of Ritonavir can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Ritonavir.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Ritonavir.
LosartanThe serum concentration of Ritonavir can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ritonavir.
LovastatinThe metabolism of Ritonavir can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Ritonavir can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Ritonavir can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Ritonavir.
LumefantrineThe metabolism of Ritonavir can be decreased when combined with Lumefantrine.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Ritonavir.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Ritonavir.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Ritonavir.
MaprotilineThe serum concentration of Ritonavir can be increased when it is combined with Maprotiline.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Ritonavir.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Ritonavir.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Ritonavir.
MebendazoleThe serum concentration of Ritonavir can be increased when it is combined with Mebendazole.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ritonavir.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Ritonavir.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Ritonavir.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Ritonavir.
MefloquineThe serum concentration of Ritonavir can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Ritonavir can be increased when it is combined with Megestrol acetate.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Ritonavir.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Ritonavir.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Ritonavir.
MeprobamateThe serum concentration of Ritonavir can be increased when it is combined with Meprobamate.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Ritonavir.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Ritonavir.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Ritonavir.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Ritonavir.
MethadoneThe serum concentration of Ritonavir can be increased when it is combined with Methadone.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Ritonavir.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Ritonavir.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Ritonavir.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Ritonavir.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Ritonavir.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Ritonavir.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Ritonavir.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Ritonavir.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Ritonavir.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Ritonavir.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Ritonavir.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Ritonavir.
MetoprololThe serum concentration of Ritonavir can be increased when it is combined with Metoprolol.
MetronidazoleThe risk or severity of adverse effects can be increased when Ritonavir is combined with Metronidazole.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Ritonavir.
MianserinThe metabolism of Mianserin can be decreased when combined with Ritonavir.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Ritonavir.
MibefradilThe serum concentration of Ritonavir can be increased when it is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Ritonavir.
MiconazoleThe serum concentration of Ritonavir can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ritonavir.
MidazolamThe serum concentration of Ritonavir can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Ritonavir.
MifepristoneThe metabolism of Ritonavir can be decreased when combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ritonavir.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Ritonavir.
MinaprineThe metabolism of Minaprine can be decreased when combined with Ritonavir.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Ritonavir.
MirabegronThe metabolism of Ritonavir can be decreased when combined with Mirabegron.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Ritonavir.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ritonavir.
MitomycinThe serum concentration of Ritonavir can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Ritonavir can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Ritonavir.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Ritonavir.
ModafinilThe serum concentration of Ritonavir can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Ritonavir.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Ritonavir.
MontelukastThe metabolism of Montelukast can be decreased when combined with Ritonavir.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Ritonavir.
MorphineThe serum concentration of Ritonavir can be increased when it is combined with Morphine.
MoxifloxacinRitonavir may increase the QTc-prolonging activities of Moxifloxacin.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Ritonavir.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Ritonavir.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Ritonavir.
NafcillinThe serum concentration of Ritonavir can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ritonavir.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Ritonavir.
NaltrexoneThe serum concentration of Ritonavir can be increased when it is combined with Naltrexone.
NaproxenThe metabolism of Naproxen can be decreased when combined with Ritonavir.
NaringeninThe serum concentration of Ritonavir can be increased when it is combined with Naringenin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Ritonavir.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Ritonavir.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Ritonavir.
NefazodoneThe serum concentration of Ritonavir can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Ritonavir can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Ritonavir can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Ritonavir can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Ritonavir.
NevirapineThe metabolism of Ritonavir can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Ritonavir.
NicardipineThe serum concentration of Ritonavir can be increased when it is combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Ritonavir.
NicotineThe metabolism of Nicotine can be decreased when combined with Ritonavir.
NifedipineThe serum concentration of Ritonavir can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Ritonavir.
NilotinibThe metabolism of Ritonavir can be decreased when combined with Nilotinib.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Ritonavir.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Ritonavir.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ritonavir.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Ritonavir.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Ritonavir.
NitrazepamThe serum concentration of Ritonavir can be increased when it is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Ritonavir.
NitrendipineThe serum concentration of Ritonavir can be increased when it is combined with Nitrendipine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Ritonavir.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Ritonavir.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Ritonavir.
NorethisteroneThe serum concentration of Ritonavir can be decreased when it is combined with Norethisterone.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Ritonavir.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Ritonavir.
OfloxacinRitonavir may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Ritonavir.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Ritonavir.
OlaparibThe metabolism of Ritonavir can be decreased when combined with Olaparib.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Ritonavir.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Ritonavir.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Ritonavir.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Ritonavir.
OmeprazoleThe serum concentration of Ritonavir can be increased when it is combined with Omeprazole.
OndansetronRitonavir may increase the QTc-prolonging activities of Ondansetron.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Ritonavir.
OsimertinibThe serum concentration of Ritonavir can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Ritonavir.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Ritonavir.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Ritonavir.
OxycodoneThe risk or severity of adverse effects can be increased when Ritonavir is combined with Oxycodone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Ritonavir.
P-NitrophenolThe serum concentration of Ritonavir can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Ritonavir.
PaclitaxelThe serum concentration of Ritonavir can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Ritonavir can be increased when it is combined with Palbociclib.
PaliperidoneRitonavir may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Ritonavir can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Ritonavir.
PanobinostatRitonavir may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Ritonavir can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Ritonavir.
PantoprazoleThe serum concentration of Ritonavir can be increased when it is combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Ritonavir.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Ritonavir.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Ritonavir.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Ritonavir.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Ritonavir.
ParoxetineThe serum concentration of Ritonavir can be increased when it is combined with Paroxetine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Ritonavir.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ritonavir.
Peginterferon alfa-2bThe serum concentration of Ritonavir can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineRitonavir may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe metabolism of Ritonavir can be increased when combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Ritonavir.
PerflutrenRitonavir may increase the QTc-prolonging activities of Perflutren.
PergolideThe metabolism of Pergolide can be decreased when combined with Ritonavir.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Ritonavir.
PerindoprilThe serum concentration of Ritonavir can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Ritonavir.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Ritonavir.
PethidineThe risk or severity of adverse effects can be increased when Ritonavir is combined with Pethidine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Ritonavir.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Ritonavir.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Ritonavir.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Ritonavir.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Ritonavir.
PhenytoinThe serum concentration of Ritonavir can be decreased when it is combined with Phenytoin.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Ritonavir.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Ritonavir.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Ritonavir.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Ritonavir.
PindololThe metabolism of Pindolol can be decreased when combined with Ritonavir.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ritonavir.
PiperazineThe metabolism of Piperazine can be decreased when combined with Ritonavir.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Ritonavir.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Ritonavir.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Ritonavir.
Platelet Activating FactorThe serum concentration of Ritonavir can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Ritonavir.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Ritonavir.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Ritonavir.
PonatinibThe serum concentration of Ritonavir can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Ritonavir can be increased when it is combined with Posaconazole.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Ritonavir.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Ritonavir.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Ritonavir.
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Ritonavir resulting in a loss in efficacy.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Ritonavir.
PravastatinThe serum concentration of Ritonavir can be increased when it is combined with Pravastatin.
PrazepamThe metabolism of Prazepam can be decreased when combined with Ritonavir.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Ritonavir.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Ritonavir.
PrazosinThe serum concentration of Ritonavir can be increased when it is combined with Prazosin.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Ritonavir.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ritonavir.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ritonavir.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Ritonavir.
PrimaquineRitonavir may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Ritonavir can be increased when combined with Primidone.
ProbenecidThe serum concentration of Ritonavir can be increased when it is combined with Probenecid.
ProcainamideRitonavir may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Ritonavir.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Ritonavir.
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Ritonavir.
PromazineRitonavir may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Ritonavir can be decreased when combined with Promazine.
PromethazineThe serum concentration of Ritonavir can be increased when it is combined with Promethazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Ritonavir.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Ritonavir.
PropofolThe metabolism of Propofol can be decreased when combined with Ritonavir.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Ritonavir.
PropranololThe serum concentration of Ritonavir can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Ritonavir.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ritonavir.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Ritonavir.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Ritonavir.
QuazepamThe serum concentration of Ritonavir can be increased when it is combined with Quazepam.
QuazepamThe metabolism of Quazepam can be decreased when combined with Ritonavir.
QuercetinThe serum concentration of Ritonavir can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Ritonavir.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Ritonavir.
QuinacrineThe serum concentration of Ritonavir can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Ritonavir.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Ritonavir.
QuinineThe serum concentration of Ritonavir can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Ritonavir.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Ritonavir.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Ritonavir.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Ritonavir.
RanitidineThe serum concentration of Ritonavir can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ritonavir can be increased when it is combined with Ranolazine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Ritonavir.
ReboxetineThe serum concentration of Ritonavir can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Ritonavir.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Ritonavir.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Ritonavir.
repinotanThe metabolism of repinotan can be decreased when combined with Ritonavir.
ReserpineThe serum concentration of Ritonavir can be decreased when it is combined with Reserpine.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Ritonavir.
RifabutinThe serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Ritonavir.
RifabutinThe metabolism of Ritonavir can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Ritonavir can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Ritonavir can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ritonavir.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Ritonavir.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Ritonavir.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Ritonavir.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Ritonavir.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Ritonavir.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Ritonavir.
RolapitantThe serum concentration of Ritonavir can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ritonavir.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Ritonavir.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Ritonavir.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ritonavir.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ritonavir.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Ritonavir.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Ritonavir.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Ritonavir.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Ritonavir.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Ritonavir.
SaquinavirRitonavir may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe serum concentration of Ritonavir can be decreased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Ritonavir.
ScopolamineThe serum concentration of Ritonavir can be increased when it is combined with Scopolamine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Ritonavir.
SelegilineThe serum concentration of Ritonavir can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Ritonavir.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Ritonavir.
SertindoleThe metabolism of Sertindole can be decreased when combined with Ritonavir.
SertralineThe metabolism of Sertraline can be decreased when combined with Ritonavir.
SertralineThe serum concentration of Ritonavir can be increased when it is combined with Sertraline.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Ritonavir.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Ritonavir.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Ritonavir.
SildenafilThe metabolism of Ritonavir can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ritonavir.
SiltuximabThe serum concentration of Ritonavir can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ritonavir can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ritonavir.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Ritonavir.
SirolimusThe serum concentration of Ritonavir can be decreased when it is combined with Sirolimus.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Ritonavir.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Ritonavir.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Ritonavir.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Ritonavir.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Ritonavir.
SotalolRitonavir may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Ritonavir.
SparteineThe metabolism of Sparteine can be decreased when combined with Ritonavir.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Ritonavir.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Ritonavir.
SpironolactoneThe serum concentration of Ritonavir can be increased when it is combined with Spironolactone.
St. John's WortThe metabolism of Ritonavir can be increased when combined with St. John's Wort.
StaurosporineThe serum concentration of Ritonavir can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Ritonavir can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Ritonavir can be decreased when it is combined with Streptozocin.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Ritonavir.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Ritonavir.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Ritonavir.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Ritonavir.
SulfinpyrazoneThe serum concentration of Ritonavir can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleRitonavir may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Ritonavir can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ritonavir.
SumatriptanThe serum concentration of Ritonavir can be increased when it is combined with Sumatriptan.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Ritonavir.
SunitinibThe serum concentration of Ritonavir can be increased when it is combined with Sunitinib.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Ritonavir.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Ritonavir.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Ritonavir.
TacrineThe serum concentration of Ritonavir can be increased when it is combined with Tacrine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Ritonavir.
TacrolimusThe serum concentration of Ritonavir can be decreased when it is combined with Tacrolimus.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Ritonavir.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ritonavir resulting in a loss in efficacy.
TamoxifenThe serum concentration of Ritonavir can be decreased when it is combined with Tamoxifen.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Ritonavir.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Ritonavir.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Ritonavir.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Ritonavir.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Ritonavir.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Ritonavir.
Taurocholic AcidThe serum concentration of Ritonavir can be increased when it is combined with Taurocholic Acid.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Ritonavir.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Ritonavir.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Ritonavir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Ritonavir.
TelaprevirThe metabolism of Ritonavir can be decreased when combined with Telaprevir.
TelavancinRitonavir may increase the QTc-prolonging activities of Telavancin.
TelithromycinRitonavir may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Ritonavir can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Ritonavir can be increased when it is combined with Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Ritonavir.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Ritonavir.
TemsirolimusThe serum concentration of Ritonavir can be increased when it is combined with Temsirolimus.
TeniposideThe metabolism of Teniposide can be decreased when combined with Ritonavir.
TenofovirThe metabolism of Ritonavir can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Ritonavir can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Ritonavir.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Ritonavir.
TeriflunomideThe serum concentration of Ritonavir can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Ritonavir.
TesmilifeneThe serum concentration of Ritonavir can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Ritonavir.
TestosteroneThe serum concentration of Ritonavir can be increased when it is combined with Testosterone.
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Ritonavir.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Ritonavir.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Ritonavir.
TheophyllineThe metabolism of Ritonavir can be decreased when combined with Theophylline.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Ritonavir.
ThioridazineThe metabolism of Ritonavir can be decreased when combined with Thioridazine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Ritonavir.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Ritonavir.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Ritonavir.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Ritonavir resulting in a loss in efficacy.
TicagrelorThe serum concentration of Ritonavir can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Ritonavir can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Ritonavir.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Ritonavir.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Ritonavir.
TipranavirThe serum concentration of Ritonavir can be decreased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Ritonavir.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Ritonavir.
TocilizumabThe serum concentration of Ritonavir can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Ritonavir.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ritonavir.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ritonavir.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Ritonavir.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ritonavir.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ritonavir.
TorasemideThe metabolism of Torasemide can be decreased when combined with Ritonavir.
ToremifeneThe risk or severity of adverse effects can be increased when Ritonavir is combined with Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Ritonavir.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ritonavir.
TranylcypromineThe metabolism of Ritonavir can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Ritonavir.
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Ritonavir.
TrazodoneThe serum concentration of Ritonavir can be decreased when it is combined with Trazodone.
TreprostinilThe serum concentration of Treprostinil can be increased when it is combined with Ritonavir.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Ritonavir.
TriamcinoloneThe risk or severity of adverse effects can be increased when Ritonavir is combined with Triamcinolone.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Ritonavir.
TrifluoperazineThe serum concentration of Ritonavir can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Ritonavir can be increased when it is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Ritonavir.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Ritonavir.
TrimethoprimThe serum concentration of Ritonavir can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Ritonavir.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Ritonavir.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Ritonavir.
TroleandomycinThe serum concentration of Ritonavir can be increased when it is combined with Troleandomycin.
UdenafilThe metabolism of Udenafil can be decreased when combined with Ritonavir.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ritonavir.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Ritonavir.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Ritonavir.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Ritonavir.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Ritonavir.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Ritonavir.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Ritonavir.
VemurafenibThe serum concentration of Ritonavir can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Ritonavir can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Ritonavir.
VerapamilThe metabolism of Ritonavir can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Ritonavir.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Ritonavir.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Ritonavir.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Ritonavir.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ritonavir.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Ritonavir.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ritonavir.
VincristineThe serum concentration of Ritonavir can be decreased when it is combined with Vincristine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Ritonavir.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Ritonavir.
VinorelbineThe serum concentration of Ritonavir can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Ritonavir.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Ritonavir.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Ritonavir.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Ritonavir.
VoriconazoleThe metabolism of Ritonavir can be decreased when combined with Voriconazole.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Ritonavir.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Ritonavir.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Ritonavir.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Ritonavir.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Ritonavir.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Ritonavir.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Ritonavir.
ZileutonThe metabolism of Zileuton can be decreased when combined with Ritonavir.
ZimelidineThe serum concentration of Ritonavir can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Ritonavir can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Ritonavir.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Ritonavir.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Ritonavir.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Ritonavir.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Ritonavir.
Food Interactions
  • Avoid St.John's Wort.
  • Take with food.

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Aspartic-type endopeptidase activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72874
Molecular Weight:
10778.7 Da
References
  1. Garriga C, Perez-Elias MJ, Delgado R, Ruiz L, Najera R, Pumarola T, Alonso-Socas Mdel M, Garcia-Bujalance S, Menendez-Arias L: Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol. 2007 Nov;79(11):1617-28. [PubMed:17854027 ]
  2. Das A, Rao DR, Hosur MV: X-ray structure of HIV-1 protease tethered dimer complexed to ritonavir. Protein Pept Lett. 2007;14(6):565-8. [PubMed:17627597 ]
  3. Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85. [PubMed:17849388 ]
  4. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995 Dec 7;333(23):1534-9. [PubMed:7477168 ]
  5. Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH: Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci. 1997 Aug;19(4):159-75. [PubMed:9297727 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Tanabe M, Hashimoto M, Ono H: Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. Eur J Pharmacol. 2008 Jul 28;589(1-3):102-5. doi: 10.1016/j.ejphar.2008.06.013. Epub 2008 Jun 7. [PubMed:18602099 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Perloff MD, Von Moltke LL, Marchand JE, Greenblatt DJ: Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci. 2001 Nov;90(11):1829-37. [PubMed:11745741 ]
  2. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137 ]
  3. Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther. 2003 Mar;304(3):1161-71. [PubMed:12604693 ]
  4. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  5. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. [PubMed:11181899 ]
  6. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH: P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001 Apr;59(4):806-13. [PubMed:11259625 ]
  7. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  8. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Perloff MD, Von Moltke LL, Marchand JE, Greenblatt DJ: Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci. 2001 Nov;90(11):1829-37. [PubMed:11745741 ]
  2. Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP: The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS. 2002 Sep 6;16(13):1743-7. [PubMed:12218384 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM: Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem. 2001 Sep 7;276(36):33309-12. Epub 2001 Jul 20. [PubMed:11466304 ]
  2. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH: Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS. 2002 Nov 22;16(17):2295-301. [PubMed:12441801 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Gupta A, Zhang Y, Unadkat JD, Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004 Jul;310(1):334-41. Epub 2004 Mar 8. [PubMed:15007102 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. [PubMed:12490595 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 03:39